Qenta and Netcetera - securing cashless payments in the CEE region
16.6.2022 18:36:00 EEST | Business Wire | Press release
2022 continues with a dynamic tempo for Swiss payment expert Netcetera. Starting from June, Netcetera stepped into direct collaboration with Qenta Payment CEE, by being a reliable expert provider and enabling its secure 3DS technology for the Austrian payment gateway.
"We have been using Netcetera’s reliable 3DS technology for several years via our partner networks. We have now chosen to collaborate even more closely and are happy to have Netcetera as our direct technology partner. This partnership provides us with access to the latest payments industry innovations and information, as well as reliable, 24/7 support. For us, the decisive factor to work so closely with Netcetera was their deep industry knowledge and the consistency that Netcetera provides to its customers. Their 3DS SaaS product has allowed us to continue our successful legacy of cashless payment protection in the CEE region. We are pleased to continue developing this partnership both today and in the future." Wolfgang Harder-Pachernegg, VP of Payment Products.
Qenta offers its customers an interface for e-commerce payment systems which can be easily integrated into merchants’ payments process chain. This Austrian payment provider has over 20 years of expertise as a provider of both offline and online payment solutions tailored to their customer’s needs. Through the usage of Netcetera’s 3DS SaaS product, Qenta is to continue providing its customers compelling business benefits such as improved conversions, optimized checkout processes, reduced fraud, and protection from fraudulent chargeback liability.
"We are happy to work with Qenta and to jointly push towards progress in our dynamic industry. Our goal is to guarantee secure online payments for the Qenta customers spread around the whole CEE region. Our 3DS server means excellent service availability and supporting the needs of the provider 24/7." stated Petra Paul, Senior Sales Executive Digital Finance at Netcetera.
Netcetera’s acquiring products enable users to process transactions with 3-D Secure protocols and PSD2 SCA exemptions, certified with the biggest card networks and fully compliant with the standards in the payment industry such as PCI – DSS and PCI-3DS.
Netcetera provides continuous upgrades and updates to support all new trends and client requirements in the payment industry. It constantly monitors, tests and reports in order to offer the best consultancy services to its customers on how to overcome challenges, to improve their conversion rates and to secure their overall fintech business.
About Netcetera
Netcetera is a global software company with cutting-edge IT products and individual digital solutions in the areas of secure digital payment, financial technologies, media, transport, healthcare and insurance. More than 500 banks and issuers, and 160,000 merchants rely on the digital payment solutions and globally certified 3-D Secure products of the market leader for payment security. The owner-managed company covers the entire IT lifecycle, from ideation and strategy to implementation and operation. The balanced combination of the latest technologies and proven standards ensures investment security, from large-scale projects to innovative start-ups. Founded in 1996, Netcetera is a holding company with around 800 employees and is headquartered in Zurich, Switzerland, with locations across Europe, Asia, and the Middle East.
Further information: netcetera.com
About QENTA Payment CEE
Expertise from over 20 years as a provider of payment solutions.
QENTA Payment CEE has been offering you the latest technologies in cashless payment processing for more than 20 years and supports you in developing international payment strategies tailored to your sales channels. As an Austrian payment service provider, we accompany you through all phases of your business development. Our payment solutions, offline and online payments, are individually tailored to your needs and thus make the difference in the area of e-payment. Let one of the most experienced payment service providers advise you. Our team is at your side personally, competently and with commitment.
Further information: qenta.com
Additional features:
File: Qenta&Netcetera_en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005727/en/
Contact information
Media contact
Netcetera
Angelika Seiler
Head of Content
angelika.seiler@netcetera.com
+41 44 297 58 09
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom